Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT07398950
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ATTR-CM AI-ECG and AI-Echo Model — DIAGNOSTIC_TEST
    AI-based sequential screening approach for ATTR-CM

Study Details

The TRACE-AI Diagnostic Study will evaluate the performance of artificial intelligence (AI) models applied to electrocardiograms (AI-ECG) and echocardiograms (AI-Echo) to identify transthyretin amyloid cardiomyopathy (ATTR-CM) in adults with heart failure. Model performance will be validated through comparison with technetium-99m pyrophosphate (PYP) imaging results.

Key Dates

Start date
Mar 31, 2026
Status verified
Feb 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
150 participants (estimated)

Primary Outcome Measure

Performance of the sequential screening approach [ Time Frame: From enrollment through completion of PYP scan at baseline study visit ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Yale New Haven Health SystemNew HavenConnecticut06519
Rohan Khera, MD, MS
[email protected]
203-764-5585
Rohan Khera, MD, MS (PRINCIPAL_INVESTIGATOR)

Find similar trials in New Haven, CT

By condition
Heart failure
By specialty
CardiologyHeart disease
By research site
Yale New Haven Health System· New Haven, CT

Related Studies